Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Resubmit Following Additional Data Analyses

Paris (France), Friday 13 August, 2021– Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following very recent discussions with the U.S. Food and Drug Administration (FDA), withdrawal of the New Drug Application (NDA) for palovarotene....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news